Peapod Lane Capital LLC reduced its position in Ikena Oncology, Inc. (NASDAQ:IKNA - Free Report) by 41.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 296,437 shares of the company's stock after selling 211,431 shares during the period. Peapod Lane Capital LLC owned about 0.61% of Ikena Oncology worth $379,000 as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. Squarepoint Ops LLC purchased a new position in shares of Ikena Oncology in the fourth quarter worth approximately $72,000. BNP Paribas Financial Markets purchased a new position in Ikena Oncology during the fourth quarter valued at approximately $72,000. Northern Trust Corp grew its position in Ikena Oncology by 19.7% during the fourth quarter. Northern Trust Corp now owns 57,565 shares of the company's stock valued at $94,000 after purchasing an additional 9,456 shares in the last quarter. Gilead Sciences Inc. purchased a new position in Ikena Oncology during the fourth quarter valued at approximately $3,294,000. Finally, Geode Capital Management LLC grew its position in Ikena Oncology by 21.0% during the fourth quarter. Geode Capital Management LLC now owns 327,962 shares of the company's stock valued at $538,000 after purchasing an additional 56,936 shares in the last quarter. 75.00% of the stock is owned by hedge funds and other institutional investors.
Ikena Oncology Price Performance
IKNA traded down $0.01 on Friday, reaching $1.38. 40,273 shares of the company traded hands, compared to its average volume of 114,988. The stock's 50 day moving average price is $1.27 and its 200-day moving average price is $1.34. Ikena Oncology, Inc. has a 52-week low of $0.97 and a 52-week high of $1.94. The company has a market cap of $66.60 million, a price-to-earnings ratio of -1.60 and a beta of 0.50.
Ikena Oncology (NASDAQ:IKNA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.03. As a group, equities research analysts forecast that Ikena Oncology, Inc. will post -0.91 earnings per share for the current fiscal year.
Ikena Oncology Profile
(
Free Report)
Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.
Featured Articles
Before you consider Ikena Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ikena Oncology wasn't on the list.
While Ikena Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
